Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors

NCT00085878 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor Cancer

Interventions

DRUG: SB-485232

Sponsor

GlaxoSmithKline